Een plasje in de strijd tegen hartfalen
Stel je voor: geen dure scan, ingewikkelde bloedtest of ellenlange ziekenhuisopname nodig om te weten of je hart gevaar loopt. Een simpel plasje kan voldoende zijn. Klinkt banaal, maar net daar ligt de sleutel tot een revolutionaire aanpak van hartfalen. Evelyne Meekers, onderzoekster in Ziekenhuis Oost-Limburg en UHasselt, wijdde haar onderzoek aan dit idee. Conclusie: een druppel urine kan artsen en patiënten tijdig waarschuwen voor dreigende problemen – en zo hopelijk levens redden.
Hartfalen: een groeiend probleem
Hartfalen is een van de grootste gezondheidsuitdagingen van onze tijd. In België leven meer dan 250.000 mensen met deze diagnose, en daar komen jaarlijks nog eens 20.000 nieuwe patiënten bij.
Voor patiënten betekent hartfalen vaak een vicieuze cirkel: kortademigheid, vermoeidheid, gezwollen benen, een opname in het ziekenhuis – en daarna de angst dat het opnieuw fout loopt. En dat gebeurt helaas vaak: één op vier patiënten belandt binnen drie maanden na ontslag opnieuw op spoed. Voor de samenleving tikt de rekening hard aan: 2% van het totale gezondheidszorgbudget gaat naar hartfalen.
Ons hart en… zout
Bij hartfalen pompt het hart minder krachtig, waardoor vocht opstapelt in het lichaam. De boosdoener? Zout.
Patiënten met hartfalen plassen te weinig zout uit, waardoor hun lichaam zout en vocht opstapelt. Dat zout kunnen we dus makkelijk meten in de urine. Hoe minder zout iemand uitplast, hoe groter de kans op problemen. Het klinkt eenvoudig, maar dit inzicht kan artsen helpen om sneller en preciezer te handelen.
Van laboratorium naar nachtkastje
Tot nu toe werd hartfalen opgevolgd met vrij ruwe methodes: zichzelf dagelijks wegen en klachten bijhouden. Momenteel de beste methodes, maar helaas weinig betrouwbaar. Gewicht schommelt om allerlei redenen, en klachten zijn vaak te laat een alarmsignaal.
Daarom onderzocht Evelyne Meekers of een eenvoudige urinetest betere informatie biedt. Ze werkte met een draagbaar toestelletje dat binnen 30 seconden een resultaat geeft. Geen labo, geen wachttijden. Gewoon een druppel urine, en klaar. En perfect uitvoerbaar door de artsen, verpleegkundigen en patiënt zelf.
Wat zegt een plasje?
De resultaten in het ziekenhuis waren duidelijk. Bij een opname krijgen patiënten vochtafdrijvende medicatie om overtollig vocht en zout kwijt te raken. Maar niet elke dosis werkt voor iedereen even goed. Wanneer het zoutgehalte in de urine laag blijft na de medicatie, reageert de patiënt minder goed en moet de medicatie opgehoogd worden. Door dat tijdig te weten, kan sneller de therapie worden aangepast.
De EASY-HF studie
Een van de opvallendste onderzoeken was de EASY-HF. In deze studie werden patiënten met hartfalen en vochtopstapeling opgedeeld in twee groepen. De ene groep kreeg de klassieke behandeling: de arts bepaalde de medicatie. In de andere groep volgden verpleegkundigen een vast schema waarbij ze het zout in de urine maten en de behandeling daarop afstemden.
Het resultaat: patiënten in de tweede groep plasten duidelijk meer zout en vocht uit, en voelden zich sneller beter. Bovendien bleek het toestelletje gebruiksvriendelijk voor de verpleegkundigen.
Het onderzoeksteam is overtuigd : “Een stap dichter bij gepersonaliseerde zorg voor onze hartfalen patiënt; waardoor we sneller de juiste dosis voor de juiste patiënt vinden en de patiënt zo hopelijk sneller klachtenvrij terug thuis krijgen”.
Thuismeten: de controle in eigen handen
In haar onderzoek gaat Evelyne Meekers na of patiënten hun behandeling zelf kunnen bijsturen met een simpele urinetest. Patiënten die dagelijks vochtafdrijvende medicatie namen, gebruikten het meettoestel om te kijken of hun urine voldoende zout bevatte. Als de waarde steeg, bleek de afbouw veilig én haalbaar. Patiënten kunnen zo zelf mee hun therapie sturen, zonder dat hun gezondheid in gevaar komt.
Voor veel patiënten geeft dit een gevoel van controle en vrijheid. Geen onnodige pillen op dagen dat het lichaam ze niet nodig heeft, en minder risico op bijwerkingen zoals uitdroging of te lage bloeddruk.
Of urinemetingen thuis ook ziekenhuisopnames kunnen voorkomen, moet verder onderzoek uitwijzen. Maar de EASY-STOP resultaten tonen alvast dat patiënten actief en veilig kunnen deelnemen aan hun eigenbehandeling.
De weg naar een persoonlijke behandeling
Een belangrijk voordeel van deze aanpak is dat de behandeling eindelijk echt gepersonaliseerd kan worden. Tot nu toe kregen de meeste patiënten dezelfde medicijnen in ongeveer dezelfde dosissen. Maar hartfalen is geen “one size fits all”-ziekte. Het verloop verschilt van persoon tot persoon, en zelfs bij één patiënt kan de situatie dagelijks veranderen.
Door zout in de urine te meten, krijgen artsen een unieke inkijk in hoe het lichaam functioneert. Dat maakt het mogelijk om preciezer en sneller beter bij te sturen. Het is alsof de arts een kompas in handen krijgt, waarmee hij of zij beter kan navigeren.
Van dokterskamer tot beleid
Dit onderzoek heeft niet alleen gevolgen voor patiënten en artsen, maar ook voor het beleid. Als patiënten sneller en beter reageren op hun behandeling, scheelt dat ziekenhuisdagen en kosten. Bovendien kan de druk op de ziekenhuizen afnemen – een belangrijk punt in een tijd waarin de zorgsector kreunt onder personeelstekorten en stijgende kosten.
Het idee dat een eenvoudige, goedkope meting een groot verschil kan maken, is bijzonder aantrekkelijk. Het toont dat innovatie in de zorg niet altijd draat om dure of complexe technologie, maar soms letterlijk te vinden is in een druppel urine.
Het menselijke verhaal
Achter alle cijfers en grafieken zitten vooral mensen. Voor patiënten betekent deze aanpak minder angst en meer controle. Voor familieleden betekent het gemoedsrust, omdat ze weten dat hun geliefde van nabij gevolgd wordt.
Het onderzoeksteam benadrukt: “De gesprekken met patiënten en verpleegkundigen waren minstens zo belangrijk als de cijfers. Zij gaven ons telkens weer de motivatie om verder te zoeken naar praktische oplossingen.”
Conclusie
Een plasje als levenslijn: het klinkt bijna te eenvoudig om waar te zijn. Maar het onderzoek van Evelyne Meekers toont dat net die eenvoud de kracht is. Door zout in urine te meten, kan hartfalen sneller, persoonlijker en effectiever behandeld worden. Dat betekent minder ziekenhuisopnames, minder kosten en vooral: meer ademruimte voor patiënten en hun familie die dagelijks met hartfalen leven.
Of, zoals Evelyne Meekers het samenvat: “Door simpelweg naar het zout in de urine te kijken, kunnen we hartfalen slimmer en veiliger behandelen.”
Bibliografie
1. Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020 Aug;22(8):1342–56.
2. Smeets M, Vaes B, Mamouris P, Van Den Akker M, Van Pottelbergh G, Goderis G, et al. Burden of heart failure in Flemish general practices: A registry-based study in the Intego database. BMJ Open. 2019;9(1):1–9.
3. Mullens W, Damman K, Harjola V, Mebazaa A, Rocca HB, Martens P, et al. The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21:137–55.
4. Martens P, Mullens W. How to tackle congestion in acute heart failure. Korean J Intern Med. 2018;33:462–73.
5. Chioncel O, Mebazaa A, Harjola V-P, Coats AJ, Piepoli MF, Crespo-Leiro MG, et al. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017 Oct;19(10):1242–54.
6. Metra M, Davison B, Bettari L, Sun H, Edwards C, Lazzarini V, et al. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Hear Fail. 2012;5(1):54–62.
7. Dharmarajan K, Wang Y, Lin Z, Normand ST, Ross JS, Horwitz LI, et al. Association of Changing Hospital Readmission Rates With Mortality Rates After Hospital Discharge. JAMA. 2017;318(3):270–8.
8. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726.
9. Mullens W, Verbrugge FH, Nijst P, Hong W. Renal sodium avidity in heart failure : from pathophysiology to treatment strategies. Eur Heart J. 2017;38:1872–82.
10. Mullens W. The Early Intertwining of the Heart and the Kidney Through an Impaired Natriuretic Response to Acute Volume Expansion *. J Am Coll Cardiol. 2011;58(20).
11. Nijst P, Verbrugge F, Grieten L, Dupont M, Steels P, Tang WHW, et al. The Pathophysiological Role of Interstitial Sodium in Heart Failure. J Am Coll Cardiol. 2015;65(4):378–88.
12. Martens P, Nijst P, Dupont M, Mullens W. The Optimal Plasma Volume Status in Heart Failure in Relation to Clinical Outcome. J Card Fail. 2019;25(4):240–8.
13. Zile MR, Bennett TD, St. John Sutton M, Cho YK, Adamson PB, Aaron MF, et al. Transition From Chronic Compensated to Acute Decompensated Heart Failure: Pathophysiological Insights Obtained From Continuous Monitoring of Intracardiac Pressures. Circulation. 2008;118:1433–41.
14. Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure : a randomised controlled trial. Lancet. 2011;377(9766):658–66.
15. Bourge RC, Abraham WT, Adamson PB, Aaron MF, Aranda JM, Magalski A, et al. Randomized Controlled Trial on an Implantable Continuous Hemodynamic Monitor in Patients With Advanced Heart Failure: The COMPASS-HF Study. JACC. 2008;51(11):1073–9.
16. Verbrugge FH, Martens P, Boonen L, Nijst P, Verhaert D, Noyens P, et al. Loop diuretic down-titration in stable chronic heart failure is often achievable , especially when urinary chloride concentration is low. Acta Cardiol. 2017;73(4):1–7.
17. Martens P, Dupont M, Verbrugge H, Damman K, Degryse N, Nijst P, et al. Urinary Sodium Profiling in Chronic Heart Failure to Detect Development of Acute Decompensated Heart Failure. JACC Hear Fail. 2019;7(5):404–14.
18. Brinkley M, Burpee LJ, Chaudhry S, Smallwood JA, Lindenfeld J, Lakdawala NK, et al. Spot Urine Sodium as Triage for Effective Diuretic Infusion in an Ambulatory Heart Failure Unit. J Card Fail. 2018;24(6):349–54.
19. ter Maaten JM, Martens P, Damman K, Dickstein K, Ponikowski P, Lang CC, et al. Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction. Clin Res Cardiol. 2020;109(8):1048–59.
20. Damman K, Kjekshus J, Wikstrand J, Cleland JGF, Komajda M, Wedel H, et al. Loop diuretics , renal function and clinical outcome in patients with heart failure and reduced ejection fraction. Eur J Heart Fail. 2016;18:328–36.
21. Testani JM, Hanberg JS, Cheng S, Rao V, Onyebeke C, Laur O, et al. Rapid and Highly Accurate Prediction of Poor Loop Diuretic Natriuretic Response in Patients With Heart Failure. Circ Hear Fail Hear Fail. 2015;9(1):1–8.
22. Testani JM, Brisco MA, Kociol RD, Jacoby D. Substantial Discrepancy Between Fluid and Weight Loss During Acute Decompensated Heart Failure Treatment. Am J Med. 2015;128(7):776–83.
23. Ter Maaten JM, Beldhuis IE, van der Meer P, Krikken JA, Postmus D, Coster JE, et al. Natriuresis-guided diuretic therapy in acute heart failure: a pragmatic randomized trial. Nat Med. 2023 Oct;29(10):2625–32.
24. Dauw J, Charaya K, Lelonek M, Zegri-Reiriz I, Nasr S, Paredes-Paucar CP, et al. Protocolized Natriuresis-Guided Decongestion Improves Diuretic Response: the Multicenter ENACT-HF Study. Accept Circ Hear Fail.
25. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726.
26. Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020;382(20):1883–93.
27. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413–24.
28. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451–61.
29. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med. 2014;371(11):993–1004.
30. Krumholz HM, Hsieh A, Dreyer RP, Welsh J, Desai R, Dharmarajan K. Trajectories of Risk for Specific Readmission Diagnoses after Hospitalization for Heart Failure , Acute Myocardial Infarction , or Pneumonia. PLoS One. 2016;11(10):1–14.
31. Mullens W, Damman K, Testani JM, Martens P, Mueller C, Lassus J, et al. Evaluation of kidney function throughout the heart failure trajectory – a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020;22(4):584–603.
32. Cobo M, Zegri I, Paloma R, Garcia-Gomez S, Garcia-Rodriguez D, Dominguez-Rodriguez F, et al. Usefulness of natriuresis to predict in-hospital diuretic resistance. Am J Cardiovasc Dis. 2020;10(4):350–5.
33. Tersalvi G, Dauw J, Gasperetti A, Winterton D, Cioffi GM, Scopigni F, et al. The value of urinary sodium assessment in acute heart failure. Eur Hear Journal Acute Cardiovasc Care. 2021;10(2):216–23.
34. Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, et al. Importance of Venous Congestion for Worsening of Renal Function in Advanced Decompensated Heart Failure. J Am Coll Cardiol. 2009;53(7):589–96.
35. Martens P, Tang WHW, Mullens W. Renal sodium avidity, the prevailing renal target in heart failure. Eur Heart J. 2021;42(43):4478–81.
36. Verbrugge FH, Dupont M, Steels P, Grieten L, Swennen Q, Tang WHW, et al. The kidney in congestive heart failure : ‘ are natriuresis, sodium and diuretics really the good, the bad and the ugly?’ Eur J Heart Fail. 2014;16:133–42.
37. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Vol. 145, Circulation. 2022. 895–1032 p.
38. Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, et al. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload. N Engl J Med. 2022 Aug 26;387(13):1185–95.
39. Matsue Y, Damman K, Voors AA, Kagiyama N, Yamaguchi T, Kuroda S, et al. Time-to-Furosemide Treatment and Mortality in Patients Hospitalized With Acute Heart Failure. J Am Coll Cardiol. 2017;69(25).
40. Testani JM, Chen J, Mccauley BD, Kimmel SE, Shannon RP. Potential Effects of Aggressive Decongestion During the Treatment of Decompensated Heart Failure on Renal Function and Survival. Circulation. 2010;122:265–72.
41. Cox ZL, Rao VS, Testani JM. Classic and Novel Mechanisms of Diuretic Resistance in Cardiorenal Syndrome. Kidney360. 2022;3:10.34067/KID.0006372021.
42. Neuwirt H, Burtscher A, Cherney D, Mayer G, Ebenbichler C. Tubuloglomerular Feedback in Renal Glucosuria: Mimicking Long-term SGLT-2 Inhibitor Therapy. Kidney Med. 2020;2(1):76–9.
43. Verbrugge FH, Nijst P, Dupont M, Penders J, Tang WHW, Mullens W. Urinary Composition During Decongestive Treatment in Heart Failure With Reduced Ejection Fraction. Circ Hear Fail. 2014;7:766–72.
44. Rao VS, Ivey-Miranda JB, Cox ZL, Riello R, Griffin M, Fleming J, et al. Natriuretic Equation to Predict Loop Diuretic Response in Patients with Heart Failure. JACC. 2021;77(6):695–708.
45. Singh D, Shrestha K, Testani JM, Verbrugge FH, Dupont M, Mullens W, et al. Insufficient natriuretic response to continuous intravenous furosemide is associated with poor long-term outcomes in acute decompensated heart failure. J Card Fail. 2014;20(6):392–9.
46. Ward A, Heel R. Bumetanide: A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Use. Drugs. 1984;28:426–64.
47. Damman K, Ter Maaten JM, Coster JE, Krikken JA, van Deursen VM, Krijnen HK, et al. Clinical importance of urinary sodium excretion in acute heart failure. Eur J Heart Fail. 2020;22(8):1438–47.
48. Gleason O, Meegan G, Fleming J, Griffin M, Ivey-Miranda J, Cox Z, et al. Validation of Natriuretic Response Prediction Equation in Patients with Acute Decompensated Heart Failure. J Card Fail. 2020;26(10):S2.
49. Brinkley DM, Burpee LJ, Chaudhry SP, Smallwood JA, Lindenfeld JA, Lakdawala NK, et al. Spot Urine Sodium as Triage for Effective Diuretic Infusion in an Ambulatory Heart Failure Unit. J Card Fail. 2018;24(6):349–54.
50. Galluzzo A, Frea S, Boretto P, Pidello S, Volpe A, Canavosio FG, et al. Spot urinary sodium in acute decompensation of advanced heart failure and dilutional hyponatremia: insights from DRAIN trial. Clin Res Cardiol. 2020;109(10):1251–9.
51. Tang WHW, Verbrugge FH, Mullens W. Cardiorenal syndrome in heart failure. Vol. 60, Respiration and Circulation. 2020.
52. Biegus J, Zymliński R, Testani J, Marciniak D, Zdanowicz A, Jankowska EA, et al. Renal profiling based on estimated glomerular filtration rate and spot urine sodium identifies high-risk acute heart failure patients. Eur J Heart Fail. 2021;23(5):729–39.
53. García-Magallón B, Cobo-Marcos M, Martiarena AD, Hernández EM, Martín Jiménez ML, García AM, et al. Role of Early Assesment of Diuresis and Natriuresis in Detecting In-Hospital Diuretic Resistance in Acute Heart Failure. Front Physiol. 2022;13(May):1–5.
54. Ter Maaten JM, Valente MAE, Damman K, Hillege HL, Navis G, Voors AA. Diuretic response in acute heart failure - Pathophysiology, evaluation, and therapy. Nat Rev Cardiol. 2015;12(3):184–92.
55. Elias C, Oliveira D, Soares-Carreira M, Amorim M, Araújo JP, Bettencourt P, et al. The ratio of furosemide dosage to urinary sodium concentration predicts mortality in patients with chronic stable heart failure. Polish Arch Intern Med. 2021;131(10):1–8.
56. Verbrugge FH, Nijst P, Dupont M, Reynders C, Penders J, Tang WHW, et al. Prognostic Value of Glomerular Filtration Changes Versus Natriuretic Response in Decompensated Heart Failure With Reduced Ejection. J Card Fail. 2014;20(11):817–24.
57. H. Verbrugge F, Dupont M, B. Bertrand P, Nijst P, Penders J, Dens J, et al. Determinants and impact of the natriuretic response to diuretic therapy in heart failure with reduced ejection fraction and volume overload. Acta Cardiol. 2015;70(3):265–73.
58. Ferreira JP, Girerd N, Medeiros PB, Santos M, Carvalho HC, Bettencourt P, et al. Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect. Clin Res Cardiol. 2016;105(6):489–507.
59. Doering A, Jenkins CA, Storrow AB, Lindenfeld JA, Fermann GJ, Miller KF, et al. Markers of diuretic resistance in emergency department patients with acute heart failure. Int J Emerg Med. 2017;10(1).
60. Luk A, Groarke JD, Desai AS, Mahmood SS, Gopal DM, Joyce E, et al. First spot urine sodium after initial diuretic identifies patients at high risk for adverse outcome after heart failure hospitalization. Am Heart J. 2018;203:95–100.
61. Honda S, Nagai T, Nishimura K, Nakai M, Honda Y, Nakano H, et al. Long-term prognostic significance of urinary sodium concentration in patients with acute heart failure. Int J Cardiol. 2018;254:189–94.
62. Collins SP, Jenkins CA, Baughman A, Miller KF, Storrow AB, Han JH, et al. Early urine electrolyte patterns in patients with acute heart failure. ESC Hear Fail. 2019;6(1):80–8.
63. Biegus J, Zymliński R, Sokolski M, Todd J, Cotter G, Metra M, et al. Serial assessment of spot urine sodium predicts effectiveness of decongestion and outcome in patients with acute heart failure. Eur J Heart Fail. 2019;21(5):624–33.
64. Hodson DZ, Griffin M, Mahoney D, Ahmad T, Turner J, Wilson FP, et al. Natriuretic Response is Highly Variable and Associated with Six-Month Survival: Insights from the ROSE-AHF Trial. JACC Hear Fail. 2019;7(5):383–91.
65. Cunningham J, Sun J, Mc Causland F, Ly S, Anstrom K, Lindenfeld J, et al. Lower urine sodium predicts longer length of stay in acute heart failure patients: Insights from the ROSE AHF trial. Clin Cardiol. 2020;43:43–9.
66. Cox ZL, Rao VS, Ivey-Miranda JB, Moreno-Villagomez J, Mahoney D, Ponikowski P, et al. Compensatory post-diuretic renal sodium reabsorption is not a dominant mechanism of diuretic resistance in acute heart failure. Eur Heart J. 2021;42(43):4468–77.
67. de la Espriella R, Núñez E, Llàcer P, García-Blas S, Ventura S, Núñez JM, et al. Early urinary sodium trajectory and risk of adverse outcomes in acute heart failure and renal dysfunction. Rev Española Cardiol (English Ed. 2021;74(7):616–23.
68. Biegus J, Zymliński R, Fudim M, Testani J, Sokolski M, Marciniak D, et al. Spot urine sodium in acute heart failure: differences in prognostic value on admission and discharge. ESC Hear Fail. 2021;8(4):2597–602.
69. Caravaca Perez P, Nuche J, Moran Fernandez L, Lora D, Blazquez-Bermejo Z, Lopez-Azor JC, et al. Potential Role of Natriuretic Response to Furosemide Stress Test during Acute Heart Failure. Circ Hear Fail. 2021;14(6):E008166.
70. Martens P, Chen HH, Verbrugge FH, Testani JT, Mullens W, Tang WHW. Assessing intrinsic renal sodium avidity in acute heart failure: implications in predicting and guiding decongestion. Eur J Heart Fail. 2022;978–87.
71. ter Maaten JM, Beldhuis IE, Meer P van der, Krikken JA, Coster JE, Nieuwland W, et al. Natriuresis-guided therapy in acute heart failure: rationale and design of the Pragmatic Urinary Sodium-based treatment algoritHm in Acute Heart Failure (PUSH-AHF) trial. Eur J Heart Fail. 2022;24:385–92.
72. Dauw J, Lelonek M, Zegri-Reiriz I, Paredes-Paucar CP, Zara C, George V, et al. Rationale and Design of the Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure Study. ESC Hear Fail. 2021;8:4685–92.
73. Ganes A, Davis JA, Virtanen JK, Voutilainen A, Tuomainen TP, Atherton JJ, et al. Urinary sodium concentration predicts time to major adverse coronary events and all-cause mortality in men with heart failure over a 28-33-year period: a prospective cohort study. BMC Cardiovasc Disord. 2022;22(1):391.
74. Dauw J, Martens P, Tersalvi G, Schouteden J, Deferm S, Gruwez H, et al. Diuretic response and effects of diuretic omission in ambulatory heart failure patients on chronic low-dose loop diuretic therapy. Eur J Heart Fail. 2021;23(7):1110–9.
75. Rohde LE, Rover MM, Figueiredo Neto JA, Danzmann LC, Bertoldi EG, Simoes M V, et al. Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy : a. Eur Heart J. 2019;40:3605–12.
76. Martens P, Verbrugge FH, Boonen L, Nijst P, Dupont M, Mullens W. Value of routine investigations to predict loop diuretic down-titration success in stable heart failure. Int J Cardiol. 2018;250:171–5.
77. Filippatos G, Zannad F. An introduction to acute heart failure syndromes: definition and classification. Heart Fail Rev. 2007 Jun;12(2):87–90.
78. Felker GM, Ellison DH, Mullens W, Cox ZL, Testani JM. Diuretic Therapy for Patients With Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Mar;75(10):1178–95.
79. Dauw J, Lelonek M, Zegri-Reiriz I, Paredes-Paucar CP, Zara C, George V, et al. Rationale and Design of the Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure Study. ESC Hear Fail. 2021 Dec;8(6):4685–92.
80. Nasab Mehrabi E, Toupchi-Khosroshahi V, Athari SS. Relationship of atrial fibrillation and N terminal pro brain natriuretic peptide in heart failure patients. ESC Hear Fail. 2023 Dec;10(6):3250–7.
81. Mullens W, Verbrugge FH, Nijst P, Martens P, Tartaglia K, Theunissen E, et al. Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial. Eur J Heart Fail. 2018;20(11):1591–600.
82. HORIBA. LAQUAtwin Na-11 [Internet]. Available from: https://www.horiba.com/int/water-quality/products/detail/action/show/Pr…
83. Meekers E, Mullens W. Spot Urinary Sodium Measurements: the Future Direction of the Treatment and Follow-up of Patients with Heart Failure. Curr Heart Fail Rep. 2023 Feb;20(1):88–100.
84. Ter Maaten JM, Beldhuis IE, van der Meer P, Krikken JA, Coster JE, Nieuwland W, et al. Natriuresis-guided therapy in acute heart failure: rationale and design of the Pragmatic Urinary Sodium-based treatment algoritHm in Acute Heart Failure (PUSH-AHF) trial. Eur J Heart Fail. 2022 Feb;24(2):385–92.
85. Rao VS, Ivey-Miranda JB, Cox ZL, Riello R, Griffin M, Fleming J, et al. Natriuretic Equation to Predict Loop Diuretic Response in Patients With Heart Failure. J Am Coll Cardiol. 2021 Feb;77(6):695–708.
86. Meegan G, Sangkachand P, O’Brien M, Riello R, Soucier R, Jacoby D, et al. Safety and Efficacy of an Automated Nurse-Driven Diuretic Titration Protocol: the Yale Diuretic Pathway. J Card Fail. 2020 Oct 1;26:S22.
87. Tsutsui H, Albert NM, Coats AJS, Anker SD, Bayes-Genis A, Butler J, et al. Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society. Eur J Heart Fail. 2023 May;25(5):616–31.
88. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic Strategies in Patients with Acute Decompensated Heart Failure. N Engl J Med. 2011;365:687–96.
89. Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris PC. Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation. 1989 Aug;80(2):299–305.
90. Cleland JG, Dargie HJ, Robertson I, Robertson JI, East BW. Total body electrolyte composition in patients with heart failure: a comparison with normal subjects and patients with untreated hypertension. Br Heart J. 1987 Sep;58(3):230–8.
91. Kalra PR, Anagnostopoulos C, Bolger AP, Coats AJS, Anker SD. The regulation and measurement of plasma volume in heart failure. J Am Coll Cardiol. 2002;39(12):1901–8.
92. Vaughan EM, Merrill JP, Relman AS. Renal Regulation of Sodium Excretion in Man. J Appl Physiol. 14(6):983–90.
93. Trullàs JC, Morales-Rull JL, Casado J, Carrera-Izquierdo M, Sánchez-Marteles M, Conde-Martel A, et al. Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. Eur Heart J. 2022;44(5):411–21.
94. Abbo A (Ronnie), Gruber A, Volis I, Aronson D, Girerd N, Kristensen SL, et al. Diuresis Efficacy in Ambulatory Congested Heart Failure Patients: Intra-patient Comparison of Three Diuretic Regimens (DEA-HF). JACC Hear Fail. 0(0).
95. Bikdeli B, Strait KM, Dharmarajan K, Partovian C, Coca SG, Kim N, et al. Dominance of furosemide for loop diuretic therapy in heart failure: time to revisit the alternatives? Vol. 61, Journal of the American College of Cardiology. United States; 2013. p. 1549–50.
96. Kapelios CJ, Greene SJ, Mentz RJ, Ikeaba U, Wojdyla D, Anstrom KJ, et al. Torsemide Versus Furosemide After Discharge in Patients Hospitalized With Heart Failure Across the Spectrum of Ejection Fraction: Findings From TRANSFORM-HF. Circ Heart Fail. 2024 Mar;17(3):e011246.
97. Verbrugge FH, Martens P, Ameloot K, Haemels V, Penders J, Dupont M, et al. Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance. Eur J Heart Fail. 2019;21(11):1415–22.
98. Delanaye P, Scheen AJ. The diuretic effects of SGLT2 inhibitors: A comprehensive review of their specificities and their role in renal protection. Diabetes Metab. 2021 Nov;47(6):101285.
99. Mordi NA, Mordi IR, Singh JS, McCrimmon RJ, Struthers AD, Lang CC. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial. Circulation. 2020 Nov;142(18):1713–24.
100. Marton A, Saffari SE, Rauh M, Sun R-N, Nagel AM, Linz P, et al. Water Conservation Overrides Osmotic Diuresis During SGLT2 Inhibition in Patients With Heart Failure. J Am Coll Cardiol. 2024 Apr;83(15):1386–98.
101. Ern Yeoh S, Osmanska J, Petrie MC, Brooksbank KJM, Clark AL, Docherty KF, et al. Dapagliflozin versus metolazone in heart failure resistant to loop diuretics. Eur Heart J. 2023 May;
102. Butler J, Anstrom KJ, Felker GM, Givertz MM, Kalogeropoulos AP, Konstam MA, et al. Efficacy and safety of spironolactone in acute heart failure: The ATHENA-HF randomized clinical trial. JAMA Cardiol. 2017;2(9):950–8.
103. Dhont S, Martens P, Meekers E, Dauw J, Verbrugge FH, Nijst P, et al. Sodium and potassium changes during decongestion with acetazolamide – A pre-specified analysis from the ADVOR trial. Eur J Heart Fail. 2023 Aug 1;25(8):1310–9.
104. Oliva‐Damaso N, Nuñez J, Soler MJ. Spot Urinary Sodium as a Biomarker of Diuretic Response in Acute Heart Failure. J Am Heart Assoc. 2023 Sep 5;12(17):e030044.
105. Guzik M, Iwanek G, Fudim M, Zymliński R, Marciniak D, Ponikowski P, et al. Spot urine sodium as a marker of urine dilution and decongestive abilities in acute heart failure. Sci Rep. 2024;14(1):1494.
106. Meekers E, Martens P, Dauw J, Gruwez H, Dhont S, Nijst P, et al. Nurse-led diuretic titration via a point-of-care urinary sodium sensor in patients with acute decompensated heart failure (EASY-HF): A single-centre, randomized, open-label study. Eur J Heart Fail. 2024 Aug;
107. Costanzo MR, Ronco C, Abraham WT, Agostoni P, Barasch J, Fonarow GC, et al. Extracorporeal Ultrafiltration for Fluid Overload in Heart Failure: Current Status and Prospects for Further Research. J Am Coll Cardiol. 2017 May;69(19):2428–45.
108. Mullens W, Abrahams Z, Francis GS, Skouri HN, Starling RC, Young JB, et al. Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol. 2008 Jul;52(3):200–7.
109. Mullens W, Abrahams Z, Francis GS, Taylor DO, Starling RC, Tang WHW. Prompt Reduction in Intra-Abdominal Pressure Following Large-Volume Mechanical Fluid Removal Improves Renal Insufficiency in Refractory Decompensated Heart Failure. J Card Fail. 2008;14(6):508–14.
110. Cox ZL, Siddiqi HK, Stevenson LW, Bales B, Han JH, Hart K, et al. Randomized controlled trial of urinE chemiStry guided aCute heArt faiLure treATmEnt (ESCALATE): Rationale and design. Am Heart J. 2023 Nov;265:121–31.
111. Verbrugge FH, Martens P, Dauw J, Nijst P, Meekers E, Augusto SNJ, et al. Natriuretic Response to Acetazolamide in Patients With Acute Heart Failure and Volume Overload. J Am Coll Cardiol. 2023 May;81(20):2013–24.
112. M. DS, M. RM, A. WS, M. TT, Kirsten HL, D. SN, et al. Hospitalizations After Heart Failure Diagnosis. J Am Coll Cardiol. 2009 Oct 27;54(18):1695–702.
113. Blumer V, Mentz RJ, Sun J-L, Butler J, Metra M, Voors AA, et al. Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure. Circ Heart Fail. 2021 Apr;14(4):e007871.
114. Gracia E, Singh P, Collins S, Chioncel O, Pang P, Butler J. The Vulnerable Phase of Heart Failure. Am J Ther. 2018;25(4):e456–64.
115. Lorenzo M, de la Espriella R, Miñana G, Núñez G, Carratalá A, Rodríguez E, et al. Role of spot urinary sodium in outpatients with heart failure. Rev Esp Cardiol (Engl Ed). 2024 Jul;
116. Emel’yanov A V, Zheleznykh EA, Kozhevnikova M V, Zektser VY, Kamalova AÉ, Privalova EV, et al. INFLUENCE OF REMOTE DIGITAL OBSERVATIONS ON QUALITY OF LIFE, COMPLIANCE, AND CLINICAL OUTCOMES IN PATIENTS WITH CHRONIC HEART FAILURE. Biomed Eng (NY). 2024;57(5):311–5.
117. Wouters F, Gruwez H, Vranken J, Vanhaen D, Daelman B, Ernon L, et al. The Potential and Limitations of Mobile Health and Insertable Cardiac Monitors in the Detection of Atrial Fibrillation in Cryptogenic Stroke Patients: Preliminary Results From the REMOTE Trial. Front Cardiovasc Med. 2022;9(April):1–9.
118. Gruwez H, Van Herendael H, Maris S, Dhont S, Meekers E, Bruckers L, et al. Effectiveness of photoplethysmography-based rhythm monitoring after atrial fibrillation ablation using a smartphone application: DIGITOTAL study. Hear Rhythm. 2024 Nov;
119. Ding H, Jayasena R, Chen SH, Maiorana A, Dowling A, Layland J, et al. The Effects of Telemonitoring on Patient Compliance With Self-Management Recommendations and Outcomes of the Innovative Telemonitoring Enhanced Care Program for Chronic Heart Failure: Randomized Controlled Trial. J Med Internet Res. 2020 Jul;22(7):e17559.
120. Dauw J, Charaya K, Lelonek M, Zegri-Reiriz I, Nasr S, Paredes-Paucar CP, et al. Protocolized Natriuresis-Guided Decongestion Improves Diuretic Response: The Multicenter ENACT-HF Study. Circ Hear Fail. 2024;17(1):E011105.
121. Mullens W, Damman K, Dhont S, Banerjee D, Bayes-Genis A, Cannata A, et al. Dietary sodium and fluid intake in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC. Eur J Heart Fail. 2024 Apr;26(4):730–41.
122. Costello HM, Johnston JG, Juffre A, Crislip GR, Gumz ML. Circadian clocks of the kidney: function, mechanism, and regulation. Physiol Rev. 2022 Oct;102(4):1669–701.
123. Volpe M, Magri P, Rao MAE, Cangianiello S, DeNicola L, Mele AF, et al. Intrarenal Determinants of Sodium Retention in Mild Heart Failure - Effects of Angiotensin-Converting Enzyme Inhibition. Hypertension. 1997;30(2):168–76.
124. Rakova N, Jüttner K, Dahlmann A, Schröder A, Linz P, Kopp C, et al. Long-term space flight simulation reveals infradian rhythmicity in human Na(+) balance. Cell Metab. 2013 Jan;17(1):125–31.
125. Wilcox CS, Testani JM, Pitt B. Pathophysiology of Diuretic Resistance and Its Implications for the Management of Chronic Heart Failure. Hypertension. 2020;76(4):1045–54.
126. Wilfried M, Petra N. Cardiac Output and Renal Dysfunction. J Am Coll Cardiol. 2016 May 17;67(19):2209–12.
127. Brater DC. Pharmacokinetics of loop diuretics in congestive heart failure. Br Heart J. 1994 Aug;72(2 Suppl):S40-3.
128. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic Strategies in Patients with Acute Decompensated Heart Failure. N Engl J Med. 2011;365:687–96.
129. Schulze PC, Bogoviku J, Westphal J, Aftanski P, Haertel F, Grund S, et al. Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF). Circulation. 2022;146(4):289–98.
130. Sorensen M V, Grossmann S, Roesinger M, Gresko N, Todkar AP, Barmettler G, et al. Rapid dephosphorylation of the renal sodium chloride cotransporter in response to oral potassium intake in mice. Kidney Int. 2013 May;83(5):811–24.
131. Martens P, Deferm S, Bertrand PB, Verbrugge FH, Ramaekers J, Verhaert D, et al. The Detrimental Effect of RA Pacing on LA Function and Clinical Outcome in Cardiac Resynchronization Therapy. JACC Cardiovasc Imaging. 2020;13(4):895–906.
132. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007 Feb;49(6):675–83.
133. Bart BA, Goldsmith SR, Lee KL, Givertz MM, O’Connor CM, Bull DA, et al. Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome. N Engl J Med. 2012;367(24):2296–304.
134. Meekers E, Martens P, Dauw J, Gruwez H, Dhont S, Nijst P, et al. Nurse-Led Diuretic Titration via a Point of Care Urinary Sodium Sensor in Patients with Acute Decompensated Heart Failure (EASY-HF): a single-centre, randomized, open label study. 2024 p. Presented at Heart Failure 2024 in Lisbon.
135. Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022;400(10367):1938–52.
136. Del Pinto R, Ferri C. Iron deficiency in heart failure: diagnosis and clinical implications. Eur Hear J Suppl J Eur Soc Cardiol. 2022 Nov;24(Suppl I):I96–9.
137. Arrigo M, Jessup M, Mullens W, Reza N, Shah AM, Sliwa K, et al. Acute heart failure. Nat Rev Dis Prim. 2020;6(1).
138. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797–805.
139. Adams KF, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149(2):209–16.
140. Mullens W, Dauw J, Martens P, Meekers E, Nijst P, Verbrugge FH, et al. Acetazolamide in Decompensated Heart Failure with Volume Overload trial (ADVOR): baseline characteristics. Eur J Heart Fail. 2022;24(9):1601–10.
141. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129-2200m.
142. Mebazaa A, Parissis J, Porcher R, Gayat E, Nikolaou M, Boas FV, et al. Short-term survival by treatment among patients hospitalized with acute heart failure: The global ALARM-HF registry using propensity scoring methods. Intensive Care Med. 2011;37(2):290–301.
143. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Age- and Gender-Related Differences in Quality of Care and Outcomes of Patients Hospitalized With Heart Failure (from OPTIMIZE-HF). Am J Cardiol. 2009;104(1):107–15.
144. Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, et al. EuroHeart Failure Survey II (EHFS II): A survey on hospitalized acute heart failure patients: Description of population. Eur Heart J. 2006;27(22):2725–36.
145. Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail. 2016;18(6):613–25.
146. Arrigo M, Gayat E, Parenica J, Ishihara S, Zhang J, Choi DJ, et al. Precipitating factors and 90-day outcome of acute heart failure: a report from the intercontinental GREAT registry. Eur J Heart Fail. 2017;19(2):201–8.
147. Frömter E, Rumrich G, Ullrich KJ. Phenomenologic description of Na+, Cl- and HCO3- absorption from proximal tubules of the rat kidney. Pflügers Arch Eur J Physiol. 1973 Sep;343(3):189–220.
148. Aronson PS. Role of ion exchangers in mediating NaCl transport in the proximal tubule. Kidney Int. 1996;49(6):1665–70.
149. Palmer LG, Schnermann J. Integrated control of na transport along the nephron. Clin J Am Soc Nephrol. 2015;10(4):676–87.
150. Beloto-Silva O, Machado UF, Oliveira-Souza M. Glucose-induced regulation of NHEs activity and SGLTs expression involves the PKA signaling pathway. J Membr Biol. 2011 Dec;239(3):157–65.
151. Griffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C, et al. Empagliflozin in Heart Failure: Diuretic and Cardio-renal Effects. Circulation. 2020;142(11):1028–39.
152. Heerspink HJL, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes, Obes Metab. 2013;15:853–62.
153. Van Wilder L, Charafeddine R, Beutels P, Bruyndonckx R, Cleemput I, Demarest S, et al. Belgian population norms for the EQ-5D-5L, 2018. Qual Life Res. 2022;31(2):527–37.
154. Koh AS, Tay WT, Teng THK, Vedin O, Benson L, Dahlstrom U, et al. A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur J Heart Fail. 2017;19(12):1624–34.
155. Niederseer D, Thaler CW, Niederseer M, Niebauer J. Mismatch between heart failure patients in clinical trials and the real world. Int J Cardiol. 2013;168(3):1859–65.
156. Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet. 2018;391(10120):572–80.
157. Lund LH, Carrero JJ, Farahmand B, Henriksson KM, Jonsson Å, Jernberg T, et al. Association between enrolment in a heart failure quality registry and subsequent mortality—a nationwide cohort study. Eur J Heart Fail. 2017;19(9):1107–16.
158. Mentz RJ, Pulungan Z, Kim S, Yang M, Teigland C, Hilkert R, et al. Quality outcomes, healthcare resource utilization and costs in Medicare patients with chronic heart failure with reduced ejection fraction with and without a worsening event. J Med Econ. 2021;24(1):698–705.
159. Yaku H, Ozasa N, Morimoto T, Inuzuka Y, Tamaki Y, Yamamoto E, et al. Demographics, management, and in-hospital outcome of hospitalized acute heart failure syndrome patients in contemporary real clinical practice in Japan: Observations from the prospective, multicenter kyoto congestive heart failure (KCHF) registry. Circ J. 2018;82(11):2811–9.
160. Damman K, Valente MAE, Voors AA, O’Connor CM, Van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: An updated meta-analysis. Eur Heart J. 2014;35(7):455–69.
161. Dries DL, Exner D V., Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000;35(3):681–9.
162. Givertz MM, Postmus D, Hillege HL, Mansoor GA, Massie BM, Davison BA, et al. Renal function trajectories and clinical outcomes in acute heart failure. Circ Hear Fail. 2014;7(1):59–67.
163. Zannad F, Stein K, Garcia AA, Anker SD, Armstrong PW, Calvo G, et al. Clinical outcome endpoints in heart failure trials: A European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail. 2013;15(10):1082–94.
164. Johansson I, Joseph P, Balasubramanian K, McMurray JJV, Lund LH, Ezekowitz JA, et al. Health-Related Quality of Life and Mortality in Heart Failure The Global Congestive Heart Failure Study of 23000 Patients From 40 Countries. Circulation. 2021;143(22):2129–42.
165. Van Veldhuisen DJ, Linssen GCM, Jaarsma T, Van Gilst WH, Hoes AW, Tijssen JGP, et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol. 2013;61(14):1498–506.
166. Sanders-Van Wijk S, Van Empel V, Davarzani N, Maeder MT, Handschin R, Pfisterer ME, et al. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction. Eur J Heart Fail. 2015;17(10):1006–14.
167. Maeder MT, Rickenbacher P, Rickli H, Abbühl H, Gutmann M, Erne P, et al. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: Findings from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Eur J Heart Fail. 2013;15(10):1148–56.
168. Maeder MT, Mariani JA, Kaye DM. Hemodynamic determinants of myocardial B-type natriuretic peptide release: Relative contributions of systolic and diastolic wall stress. Hypertension. 2010;56(4):682–9.
169. Emmens JE, ter Maaten JM, Matsue Y, Figarska SM, Sama IE, Cotter G, et al. Worsening renal function in acute heart failure in the context of diuretic response. Eur J Heart Fail. 2022;24(2):365–74.
170. Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA. 2013 Dec;310(23):2533–43.
171. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May;150(9):604–12.
172. Group KDIGO (KDIGO) CW. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1–150.
173. Metra M, Nodari S, Parrinello G, Bordonali T, Bugatti S, Danesi R, et al. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. Eur J Heart Fail. 2008 Feb;10(2):188–95.
174. Waller DG, Sampson AP. Diuretics. In: Medical Pharmacology and Therapeutics (Fifth Edition). 2018. p. 21–34.
175. Martens P, Verbrugge FH, Dauw J, Nijst P, Meekers E, Augusto SN, et al. Pre-treatment bicarbonate levels and decongestion by acetazolamide: the ADVOR trial. Eur Heart J. 2023 Jun;44(22):1995–2005.
176. Trullàs JC. CLOROTIC trial: results according to glomerular filtration rate. p. 2023, May 22; ESC-HFA congress.
177. Wright EM. SGLT2 Inhibitors: Physiology and Pharmacology. Kidney360. 2021 Dec;2(12):2027–37.
178. Boorsma EM, Beusekamp JC, Ter Maaten JM, Figarska SM, Danser AHJ, van Veldhuisen DJ, et al. Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure. Eur J Heart Fail. 2021 Jan;23(1):68–78.
179. Griffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C, et al. Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects. Circulation. 2020;142(11):1028–39.
180. Kalra S, Singh V, Nagrale D. Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review. Adv Ther. 2016 Sep;33(9):1502–18.
181. Biegus J, Voors AA, Collins SP, Kosiborod MN, Teerlink JR, Angermann CE, et al. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. Eur Heart J. 2023 Jan;44(1):41–50.
182. Mount PF, Juncos LA. Obesity-Related CKD: When Kidneys Get the Munchies. Vol. 28, Journal of the American Society of Nephrology : JASN. United States; 2017. p. 3429–32.
183. Hill JA, Pauly DF, Olitsky DR, Russell S, O’Connor CM, Patterson B, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness. Jama. 2005;294(13):1625–33.
184. Fudim M, Loungani R, Doerfler SM, Coles A, Greene SJ, Cooper LB, et al. Worsening renal function during decongestion among patients hospitalized for heart failure: Findings from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial. Am Heart J. 2018 Oct;204:163–73.
185. Ahmad T, Jackson K, Rao VS, Tang WHW, Brisco-Bacik MA, Chen HH, et al. Worsening Renal Function in Patients With Acute Heart Failure Undergoing Aggressive Diuresis Is Not Associated With Tubular Injury. Circulation. 2018 May;137(19):2016–28.
186. Testani JM, McCauley BD, Chen J, Coca SG, Cappola TP, Kimmel SE. Clinical characteristics and outcomes of patients with improvement in renal function during the treatment of decompensated heart failure. J Card Fail. 2011 Dec;17(12):993–1000.
187. Testani JM, Brisco MA, Chen J, McCauley BD, Parikh CR, Tang WHW. Timing of hemoconcentration during treatment of acute decompensated heart failure and subsequent survival: importance of sustained decongestion. J Am Coll Cardiol. 2013 Aug;62(6):516–24.
188. Filippatos G, Farmakis D, Parissis J. Renal dysfunction and heart failure: things are seldom what they seem. Vol. 35, European heart journal. England; 2014. p. 416–8.
189. Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020;382(20):1884–93.
190. Mentz RJ, Anstrom KJ, Eisenstein EL, Sapp S, Greene SJ, Morgan S, et al. Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. Jama. 2023;329(3):214–23.
191. Rubio-Gracia J, Demissei BG, ter Maaten JM, Cleland JG, O’Connor CM, Metra M, et al. Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. Int J Cardiol. 2018 May 1;258:185–91.
192. Metra M, Davison B, Bettari L, Sun H, Edwards C, Lazzarini V, et al. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Hear Fail. 2012;5(1):54–62.
193. Lala A, McNulty SE, Mentz RJ, Dunlay SM, Vader JM, AbouEzzeddine OF, et al. Relief and recurrence of congestion during and after hospitalization for acute heart failure insights from diuretic optimization strategy evaluation in acute decompensated heart failure (DOSE-AHF) and cardiorenal rescue study in acute decompensated heart . Circ Hear Fail. 2015;8(4):741–8.
194. Ambrosy AP, Pang PS, Khan S, Konstam MA, Fonarow GC, Traver B, et al. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: Findings from the EVEREST trial. Eur Heart J. 2013;34(11):835–43.
195. Nohria A, Tsang SW, Fang JC, Lewis EF, Jarcho JA, Mudge GH, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol. 2003;41(10):1797–804.
196. Meekers E, Dauw J, Martens P, Dhont S, Verbrugge FH, Nijst P, et al. Renal function and decongestion with acetazolamide in acute decompensated heart failure: the ADVOR trial. Eur Heart J. 2023 Oct;44(37):3672–82.
197. Eshaghian S, Horwich TB, Fonarow GC. Relation of Loop Diuretic Dose to Mortality in Advanced Heart Failure. Am J Cardiol. 2006;97(12):1759–64.
198. Butler J, Forman DE, Abraham WT, Gottlieb SS, Loh E, Massie BM, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients11Guest Editor for this manuscript was Peter M. Okin, MD, New York Hosptial-Cornell Medical Center, New York, NY. Am Heart J. 2004;147(2):331–8.
199. Hasselblad V, Gattis Stough W, Shah MR, Lokhnygina Y, O’Connor CM, Califf RM, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail. 2007 Oct;9(10):1064–9.
200. Mebazaa A, Davison BA, Biegus J, Edwards C, Murtagh G, Varounis C, et al. Reduced congestion and improved response to a fluid/sodium challenge in chronic heart failure patients after initiation of sacubitril/valsartan: The NATRIUM-HF study. Eur J Heart Fail. 2024 Jul;26(7):1507–17.
201. John J.V. McMurray, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med. 2014;371(11):993–1004.
202. McMurray JJV, Solomon SE, Inzucchi L, Køber MN, Kosiborod FA, Martinez P, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995–2008.
203. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England). 1999 Jan;353(9146):9–13.
204. MERIT-HF study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet (London, England). 1999 Jun;353(9169):2001–7.
205. The CONSENSUS trial study Group. Enalapril for congestive heart failure. Vol. 317, The New England journal of medicine. United States; 1987. p. 1349–51.
206. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996 May;334(21):1349–55.
207. Tromp J, Ouwerkerk W, van Veldhuisen DJ, Hillege HL, Richards AM, van der Meer P, et al. A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. JACC Hear Fail. 2022;10(2):73–84.
208. Stolfo D, Lund LH, Becher PM, Orsini N, Thorvaldsen T, Benson L, et al. Use of evidence-based therapy in heart failure with reduced ejection fraction across age strata. Eur J Heart Fail. 2022 Jun;24(6):1047–62.
209. Greene SJ, Tan X, Yeh Y-C, Bernauer M, Zaidi O, Yang M, et al. Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction. Heart Fail Rev. 2022 May;27(3):741–53.
210. Savarese G, Kishi T, Vardeny O, Adamsson Eryd S, Bodegård J, Lund LH, et al. Heart Failure Drug Treatment-Inertia, Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF). JACC Heart Fail. 2023 Jan;11(1):1–14.
211. Savarese G, Lindberg F, Cannata A, Chioncel O, Stolfo D, Musella F, et al. How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC. Eur J Heart Fail. 2024;26(6):1278–97.
212. Malgie J, Wilde MI, Clephas PRD, Emans ME, Koudstaal S, Schaap J, et al. Contemporary guideline-directed medical therapy in de novo, chronic, and worsening heart failure patients: First data from the TITRATE-HF study. Eur J Heart Fail. 2024;26(7):1549–60.
213. Greene SJ, Bash LD, Tebbs KW, Hancock LN, Barlow SG, Coyle CR. Physician-Reported Reasons for Not Initiating Guideline-Directed Medical Therapy for Heart Failure. Vol. 12, JACC. Heart failure. United States; 2024. p. 2120–2.
214. Savarese G, Lindberg F, Christodorescu RM, Ferrini M, Kumler T, Toutoutzas K, et al. Physician perceptions, attitudes, and strategies towards implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. A survey of the Heart Failure Association of the ESC and the ESC Council for Cardiology Practice. Eur J Heart Fail. 2024 Jun;26(6):1408–18.
215. Duchenne J, Verbrugge FH, Dupont M, Vercammen J, Jacobs L, Grieten L, et al. Implementation of transmural disease management in patients admitted with advanced heart failure. Acta Cardiol. 2014 Apr;69(2):145–54.
216. Verbrugge FH, Duchenne J, Bertrand PB, Dupont M, Tang WHW, Mullens W. Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions. Am J Cardiol. 2013 Dec;112(12):1913–20.
217. Martens P, Verbrugge FH, Nijst P, Dupont M, Mullens W. Changes in Loop Diuretic Dose and Outcome After Cardiac Resynchronization Therapy in Patients With Heart Failure and Reduced Left Ventricular Ejection Fractions. Am J Cardiol. 2017 Jul;120(2):267–73.
218. Martens P, Verbrugge FH, Nijst P, Bertrand PB, Dupont M, Tang WH, et al. Feasibility and Association of Neurohumoral Blocker Up-titration After Cardiac Resynchronization Therapy. J Card Fail. 2017 Aug;23(8):597–605.
219. Mullens W, Auricchio A, Martens P, Witte K, Cowie MR, Delgado V, et al. Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care: A joint position statement from the Heart Failure Association (HFA), European Heart Rhythm Association (EHRA), and European Association. Eur J Heart Fail. 2020;22(12):2349–69.
220. Tan C, Dinh D, Brennan A, Hare DL, Kaye D, Lefkovits J, et al. Characteristics and Clinical Outcomes in Patients With Heart Failure With Preserved Ejection Fraction Compared to Heart Failure With Reduced Ejection Fraction: Insights From the VCOR Heart Failure Snapshot. Hear Lung Circ. 2022;31(5):623–8.
221. Brugts JJ, Radhoe SP, Clephas PRD, Aydin D, van Gent MWF, Szymanski MK, et al. Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial. Lancet (London, England). 2023 May;
222. Lindenfeld J, Zile MR, Desai AS, Bhatt K, Ducharme A, Horstmanshof D, et al. Haemodynamic-guided management of heart failure ( GUIDE-HF ): a randomised controlled trial. Lancet. 2021;398(10304):991–1001.
223. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, et al. The Global Health and Economic Burden of Hospitalizations for Heart Failure: Lessons Learned From Hospitalized Heart Failure Registries. J Am Coll Cardiol. 2014;63(12):1123–33.
224. Solomon SD, McMurray JJ V, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022 Sep;387(12):1089–98.
225. Savarese G, Xu H, Trevisan M, Dahlström U, Rossignol P, Pitt B, et al. Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. JACC Heart Fail. 2019 Jan;7(1):65–76.
226. D’Amario D, Rodolico D, Rosano GMC, Dahlström U, Crea F, Lund LH, et al. Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry. Eur J Heart Fail. 2022 May;24(5):871–84.
227. Cannon PJ. Sodium Retention in Heart Failure. Cardiol Clin. 1989;7(1):49–62.
228. Bansal S, Lindenfeld J, Schrier RW. Sodium Retention in Heart Failure and Cirrhosis. Circ Hear Fail. 2009 Jul 1;2(4):370–6.
229. Zile MR, Desai AS, Costanzo MR, Ducharme A, Maisel A, Mehra MR, et al. The GUIDE-HF trial of pulmonary artery pressure monitoring in heart failure: impact of the COVID-19 pandemic. Eur Heart J. 2022 Jul;43(27):2603–18.
230. Barasa A, Schaufelberger M, Lappas G, Swedberg K, Dellborg M, Rosengren A. Heart failure in young adults: 20-year trends in hospitalization, aetiology, and case fatality in Sweden. Eur Heart J. 2014;35(1):25–32.
231. McMurray JJ V, Adamopoulos S, Anker SD, Auricchio A. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012; The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology . Developed in collaboration. Eur Heart J. 2012;33:1787–847.
232. Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19(12):1574–85.
233. Thorvaldsen T, Benson L, Dahlström U, Edner M, Lund LH. Use of evidence-based therapy and survival in heart failure in Sweden 2003-2012. Eur J Heart Fail. 2016;18(5):503–11.
234. Rosano GMC, Moura B, Metra M, Böhm M, Bauersachs J, Ben Gal T, et al. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2021;23(6):872–81.
235. Verhestraeten C, Heggermont WA, Maris M. Clinical inertia in the treatment of heart failure: a major issue to tackle. Heart Fail Rev. 2021;26(6):1359–70.
236. Patel RB, Fonarow GC, Greene SJ, Zhang S, Alhanti B, DeVore AD, et al. Kidney Function and Outcomes in Patients Hospitalized With Heart Failure. J Am Coll Cardiol. 2021;78(4):330–43.
237. Mullens W, Martens P, Testani JM, Tang WHW, Skouri H, Verbrugge FH, et al. Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2022;24(4):603–19.
238. Greene SJ, Ayodele I, Pierce JB, Khan MS, Lewsey SC, Yancy CW, et al. Eligibility and Projected Benefits of Rapid Initiation of Quadruple Medical Therapy for Newly Diagnosed Heart Failure. JACC Hear Fail. 2024 Jul 16;
239. Malgie J, Clephas PRD, Brunner-La Rocca H-P, de Boer RA, Brugts JJ. Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy. Heart Fail Rev. 2023;28(5):1221–34.
240. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023 Oct;44(37):3627–39.
241. Beldhuis IE, Lam CSP, Testani JM, Voors AA, Van Spall HGC, Ter Maaten JM, et al. Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease. Circulation. 2022 Mar;145(9):693–712.
242. Beltrami M, Milli M, Dei LL, Palazzuoli A. The Treatment of Heart Failure in Patients with Chronic Kidney Disease: Doubts and New Developments from the Last ESC Guidelines. J Clin Med. 2022 Apr;11(8).
243. Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L, Pannaux M, et al. Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis. Eur J Heart Fail. 2018;20(9):1315–22.
244. Bansal N, Zelnick L, Bhat Z, Dobre M, He J, Lash J, et al. Burden and Outcomes of Heart Failure Hospitalizations in Adults With Chronic Kidney Disease. J Am Coll Cardiol. 2019;73(21):2691–700.
245. Claessen G, La Gerche A, Voigt J-U, Dymarkowski S, Schnell F, Petit T, et al. Accuracy of Echocardiography to Evaluate Pulmonary Vascular and RV Function During Exercise. JACC Cardiovasc Imaging. 2016 May;9(5):532–43.
246. Khedraki R, Abraham J, Jonsson O, Bhatt K, Omar HR, Bennett M, et al. Impact of exercise on pulmonary artery pressure in patients with heart failure using an ambulatory pulmonary artery pressure monitor. Front Cardiovasc Med. 2023;10(March):1–7.
